[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gain Therapeutics Inc (GANX)

Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 87,506
  • Shares Outstanding, K 43,644
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,160 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta 0.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.48

Options Overview Details

View History
  • Implied Volatility 91.86% (-37.28%)
  • Historical Volatility 74.97%
  • IV Percentile 6%
  • IV Rank 7.38%
  • IV High 810.99% on 12/10/25
  • IV Low 34.58% on 09/04/25
  • Expected Move (DTE 25) 0.28 (14.03%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 477
  • Volume Avg (30-Day) 249
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 2,253
  • Open Int (30-Day) 6,793
  • Expected Range 1.72 to 2.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 3
  • High Estimate $-0.12
  • Low Estimate $-0.13
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) +13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.66 +20.48%
on 08/03/26
2.37 -15.61%
on 08/13/26
+0.25 (+14.29%)
since 07/24/26
3-Month
1.56 +28.21%
on 06/09/26
2.37 -15.61%
on 08/13/26
+0.22 (+12.36%)
since 05/22/26
52-Week
1.53 +30.72%
on 05/19/26
4.34 -53.92%
on 12/11/25
+0.03 (+1.52%)
since 08/22/25

Most Recent Stories

More News
Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

CING : 5.68 (+2.34%)
SER : 2.63 (-8.36%)
GANX : 2.00 (-0.25%)
BIOA : 9.38 (-1.05%)
OSTX : 1.5500 (-2.52%)
VTVT : 33.89 (+1.91%)
MASS : 10.92 (+2.25%)
PYPD : 4.99 (-2.16%)
TKNO : 7.34 (-0.27%)
OVID : 2.82 (+0.71%)
MDCX : 0.2574 (-5.30%)
EQ : 2.20 (-4.76%)
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.00 (-0.25%)
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.00 (-0.25%)
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy...

GANX : 2.00 (-0.25%)
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.00 (-0.25%)
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph...

GANX : 2.00 (-0.25%)
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.00 (-0.25%)
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.00 (-0.25%)
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.00 (-0.25%)
Gain Therapeutics to Present at the 38th Annual ROTH Conference

BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 2.00 (-0.25%)

Business Summary

Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized...

See More

Key Turning Points

3rd Resistance Point 2.14
2nd Resistance Point 2.09
1st Resistance Point 2.04
Last Price 2.00
1st Support Level 1.94
2nd Support Level 1.89
3rd Support Level 1.84

See More

52-Week High 4.34
Fibonacci 61.8% 3.27
Fibonacci 50% 2.93
Fibonacci 38.2% 2.60
Last Price 2.00
52-Week Low 1.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.